GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Minnesota Attorney General Keith Ellison on Monday will share a major development in his lawsuit against three of the biggest ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Minnesota Attorney General Keith Ellison announced on Monday that a settlement has been reached Novo Nordisk over the high cost of insulin.

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue ...

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...